Author name: Leonardo Arias

Lilly Doubles Down with Nimbus, Paying $55M For Preclinical Obesity Drug

Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.

Lilly Doubles Down with Nimbus, Paying $55M For Preclinical Obesity Drug Read More »

Scroll to Top